Bafiertam
(monomethyl fumarate)PreclinicalSmall molecule
Bafiertam is one of 35 small molecule programs targeting Relapsing-Remitting Multiple Sclerosis. It is currently in Preclinical.
1
Indications
4
Total Trials
0
Active Trials
34
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
38 competitors in Relapsing-Remitting Multiple Sclerosis
#DrugCompanyPhaseTrials
1Gilenya
NovartisApproved
Tecfidera
BiogenApproved
Medrol
PfizerApproved
Celexa
AbbVieApproved
Calciferol
Jazz PharmaceuticalsApproved
Cytosar
TevaApproved
Actos
TakedaApproved
Zeposia
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Zocor
OOrganon and Co
Approved
Effexor
WWyeth-Lederle Vaccines
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Observational Study1 trial
MPA1 trial
Regulatory
FDA Approval Timeline[4]
Apr 28, 2020
BAFIERTAM
NDA NDA210296
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for monomethyl fumarate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- BBanner Life Sciences LLC